Roy Buchanan
Stock Analyst at JMP Securities
(3.69)
# 730
Out of 5,165 analysts
46
Total ratings
51.16%
Success rate
53.27%
Average return
Main Sectors:
Stocks Rated by Roy Buchanan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ASMB Assembly Biosciences | Initiates: Market Outperform | $38 | $28.17 | +34.92% | 1 | Sep 24, 2025 | |
| ENTA Enanta Pharmaceuticals | Maintains: Market Outperform | $24 → $25 | $12.70 | +96.85% | 15 | Aug 12, 2025 | |
| PYPD PolyPid | Maintains: Market Outperform | $16 → $14 | $4.19 | +234.13% | 2 | Jun 17, 2025 | |
| ANTX AN2 Therapeutics | Maintains: Market Outperform | $5 → $2 | $4.94 | -59.51% | 9 | May 5, 2025 | |
| INO Inovio Pharmaceuticals | Reiterates: Market Outperform | $18 | $1.66 | +984.34% | 3 | Mar 14, 2025 | |
| TPG TPG Inc. | Reiterates: Market Perform | n/a | $40.50 | - | 1 | Feb 13, 2025 | |
| ESPR Esperion Therapeutics | Reiterates: Market Outperform | $7 → $4 | $2.44 | +63.93% | 3 | Feb 11, 2025 | |
| IRWD Ironwood Pharmaceuticals | Maintains: Market Outperform | $23 → $14 | $3.37 | +315.43% | 1 | Jan 30, 2025 | |
| ABVX ABIVAX Société Anonyme | Reiterates: Market Outperform | $33 | $115.50 | -71.43% | 1 | Jan 10, 2025 | |
| ABUS Arbutus Biopharma | Maintains: Market Outperform | $4 → $5 | $4.26 | +17.37% | 5 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $443 → $448 | $700.45 | -36.04% | 2 | Mar 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $14 → $16 | $6.45 | +148.06% | 1 | Mar 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $2.45 | - | 2 | Feb 16, 2023 |
Assembly Biosciences
Sep 24, 2025
Initiates: Market Outperform
Price Target: $38
Current: $28.17
Upside: +34.92%
Enanta Pharmaceuticals
Aug 12, 2025
Maintains: Market Outperform
Price Target: $24 → $25
Current: $12.70
Upside: +96.85%
PolyPid
Jun 17, 2025
Maintains: Market Outperform
Price Target: $16 → $14
Current: $4.19
Upside: +234.13%
AN2 Therapeutics
May 5, 2025
Maintains: Market Outperform
Price Target: $5 → $2
Current: $4.94
Upside: -59.51%
Inovio Pharmaceuticals
Mar 14, 2025
Reiterates: Market Outperform
Price Target: $18
Current: $1.66
Upside: +984.34%
TPG Inc.
Feb 13, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $40.50
Upside: -
Esperion Therapeutics
Feb 11, 2025
Reiterates: Market Outperform
Price Target: $7 → $4
Current: $2.44
Upside: +63.93%
Ironwood Pharmaceuticals
Jan 30, 2025
Maintains: Market Outperform
Price Target: $23 → $14
Current: $3.37
Upside: +315.43%
ABIVAX Société Anonyme
Jan 10, 2025
Reiterates: Market Outperform
Price Target: $33
Current: $115.50
Upside: -71.43%
Arbutus Biopharma
Aug 2, 2024
Maintains: Market Outperform
Price Target: $4 → $5
Current: $4.26
Upside: +17.37%
Mar 3, 2023
Maintains: Market Outperform
Price Target: $443 → $448
Current: $700.45
Upside: -36.04%
Mar 1, 2023
Maintains: Market Perform
Price Target: $14 → $16
Current: $6.45
Upside: +148.06%
Feb 16, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $2.45
Upside: -